Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRAMP), recurrent glioblastoma (RGBM)

Authors
Category Primary study
JournalNeuro-Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 4ed572fcba4eceabad94e432e139ca4b76f96a75
First added on: Feb 08, 2025